

## RESEARCH CURRICULUM VITAE

<b>Name: Dr Karl Gaffney</b>		<b>DOB: 6<sup>th</sup> April 1964</b>
<b>Present appointments:</b>		
<ul style="list-style-type: none"><li>• Consultant Rheumatologist, Norfolk &amp; Norwich University Hospital NHS Foundation Trust (NNUH - 1996-) – lead clinician for spondyloarthritis and paediatric transitional care</li><li>• Honorary Reader, Norwich Medical School, University of East Anglia (2016-)</li><li>• Rheumatology Research Lead, NNUH (2013-)</li><li>• Chair, Research Leads, NNUH (2017-)</li><li>• Founder Member, Treasurer &amp; Trustee, British Society for Spondyloarthritis (2015-) <a href="http://www.britspa.co.uk">www.britspa.co.uk</a></li><li>• Chief Medical Advisor &amp; Trustee, National Ankylosing Spondylitis Society (2016-) <a href="http://www.nass.co.uk">www.nass.co.uk</a></li><li>• Invited Member, Quadram Institute Science and Strategy Steering Group, UEA (2016-)</li><li>• Invited Member, Clinical Trials Unit Executive Committee, UEA (2016-)</li></ul>		
<b>Address:</b>		
Department of Rheumatology East Block, Level 2 Norfolk and Norwich University Hospital NHS Foundation Trust Colney Lane, Norwich NR4 7UY		
<b>Telephone number:</b>	<b>Email address:</b>	
01603 289670	<a href="mailto:karl.gaffney@nnuh.nhs.uk">karl.gaffney@nnuh.nhs.uk</a>	
<b>Qualifications:</b>		
1998 MB. BCh. BAO (Hons), National University of Ireland 1988 FMGEMS 1990 MRCP 2000 FRCP (Ireland) 2004 FRCP (London)		
<b>Professional registration:</b>		
General Medical Council, 3622210, 1992		
<b>Other/Previous Appointments:</b>		
<ul style="list-style-type: none"><li>• Service Director for Rheumatology, NNUH (2008-15)</li></ul>		

- Nominated Clinical Expert, The National Institute for Health & Care Excellence for biological therapies in axial spondyloarthritis and ankylosing spondylitis (2005-) TA 143 (2008), TA 233 (2011), MTA 383 (2016), TA 350 (2016)
- Chair, British Society for Rheumatology (BSR), Axial Spondyloarthritis Biologics Guidelines Committee (2012-)
- Invited Member, Assessment of Spondyloarthritis International Society (2012-)
- Member, Arthritis Research UK, Spondyloarthritis Clinical Studies Group (2015-7)
- External Specialty Advisor for Rheumatology, London Deanery (2010-2014)
- Programme Director/Chair, Rheumatology Regional Training Committee, Eastern Deanery (2001-2012)
- Member, Rheumatology Specialty Advisory Committee, Royal College of Physicians London (2006-12)
- Director & Lecturer, MSc in Advanced Musculoskeletal Research and Practice UEA (2005-15)
- BSR Council Member & Vice-Chair, External Relations Committee (2006-2010)
- Clinical Tutor & Associate Medical Director (Education), NNUH (1999-2005)
- Arthritis Research Campaign Clinical Research Fellow, The London Hospital Medical College (1993-5)

### Research experience & personal grants awarded:

- Research Lead Rheumatology (2013-)
- Top recruiting centre, MSK NIHR portfolio studies EOE (2015-17)
- Site Lead Investigator/UK Chief Investigator for 12 NIHR portfolio studies including;
  - ✓ BSR Biologics Register (Rheumatoid Arthritis) – 810 patients recruited since 2002 – 2<sup>nd</sup> highest recruiting site nationally - >90% return rate – top recruiting centre, March-May 2017
  - ✓ BSR Biologics Register (Ankylosing Spondylitis) - 118 patients – one of 6 sites with > 100 patients – national quarterly recruitment runner-up, Jan-March and April-June 2017
  - ✓ Biosimilars - Top National Recruiting Centre 2016
- Extensive clinical trials experience - actively recruiting to 7 commercial CTIMPS (all above target, 3 – UK chief investigator), >500K NNUH income 2016-17
- Investigator-Initiated Research Grants (2012-):
  - ✓ ANSWERS : An open label, pilot, multicentre, step-down, randomised controlled trial to examine whether Etanercept 25mg once-weekly is effective in maintaining a clinical response in patients with Ankylosing Spondylitis who have responded to 50 mg once weekly (IRAS Ref 56082) (NIHR CRN Study ID: 9375). Pfizer 2012-£212,986
  - ✓ The prevalence of inflammatory back pain and spondyloarthritis in a primary care population in Norfolk: RH06S. Pfizer ICRP 2013- £52,341
  - ✓ Prevalence of axial SpA in patients presenting with anterior uveitis. AbbVie 2013 - £51,444
  - ✓ Research Capability Funding, NNUH 2015 - £20,000
  - ✓ Research Capability Funding, NNUH 2016 - £10,000
  - ✓ FOMaxS – Co-applicant - Fibromyalgia Optimal Management for patients with axial spondyloarthritis – Arthritis Research UK - £143,483.40 (Awarded December 2016)
  - ✓ The National Ankylosing Spondylitis Society - Axial Spondyloarthritis in Inflammatory Bowel Disease – secondary care cross-sectional prevalence and development of an evidence-based referral tool - [Norfolk - axial SpA IBD referral Tool (N-aspire Tool)] - £15,874 – June 2017
  - ✓ Norfolk Axial SpA Ibd REferral Computer Tomographic Strategy (N-ASPIRE CT

Strategy) – AbbVie - £106,866 - November 2017

- MD Supervisor; Drs Louise Hamilton (awarded July 2015) and Edwin Lim (in preparation)
- Grant Assessor and Manuscript Reviewer (Arthritis Research UK, Arthritis Rheumatology, Rheumatology, Arthritis Care & Research, Journal of Rheumatology, Annals of the Rheumatic Diseases, Clinical Rheumatology, BMC Rheumatology, Rheumfonds, Arthritis Ireland)
- Invited Session Chair, Meeting Convenor, Speaker – National & International Meetings – Copenhagen, Paris, Ghent, Madrid, Edinburgh, Birmingham, Leeds, Leicester, Manchester, Cheltenham, Aberdeen, Bristol, Birmingham, London, Belfast, Dublin, Liverpool, Cambridge, Paris, Helsinki (2011-7)

### **Research Collaboration/Studies In Progress**

- Chief Investigator - GoPAST - Golimumab: A UK Two-part Observational Study of its Utilisation and Impact in Patients with Ankylosing Spondylitis– A multicentre UK study in collaboration with MSD
- Can patient self-completed questionnaire predict the subsequent physician-verified diagnosis of axial spondyloarthritis - R&D Reference Number: 2014RH03L (63-04-16)
- Uveitis in axial SpA - collaboration with Scottish and Irish Registry for Ankylosing Spondylitis (SIRAS) and BSRBRAS – R&D Reference Number: 2014RH01L (45-03-14)
- Quality Standards for patients with axial SpA (in conjunction with BRITSpA, NASS & University of Glasgow) – manuscript in preparation
- SERENA CAIN457F3402 (Novartis) - SEcukinumab REal-life use iN Approved Spondyloarthritis indications-Psoriatic Arthritis, Ankylosing Spondylitis – a multicentre international study of 5000 patients - Trial Design & Steering Committee Member - Jan 2017-
- Axial Spondyloarthritis in Inflammatory Bowel Disease – secondary care cross-sectional prevalence and development of an evidence-based referral tool - [Norfolk - axial SpA IBD referral Tool (N-aspire Tool)] – in collaboration with the Department of Gastroenterology, NNUH
- Norfolk Axial SPa Ibd REferral Computer Tomographic Strategy (N-ASPIRE CT Strategy) – in collaboration with Prof Andoni Toms
- Molecular mechanisms and pathways of inflammatory and degenerative diseases: 07/H0706/81 - Professor Jagdeep Nanchahal, Kennedy Institute of Rheumatology, University of Oxford – in set-up
- Do Non-steroidal Anti-inflammatory Drugs Mask Inflammation in Spondyloarthritis on MRI (Dynamism) – collaboration with the University of Aberdeen
- FOMAxS –Fibromyalgia Optimal Management for patients with axial spondyloarthritis – in collaboration with the University of Aberdeen
- Exploring the role of anti-GMCSF monoclonal antibodies in AS – collaboration with Profs Peter Taylor and Paul Bowness - University of Oxford – in development
- Understanding sub-optimal response to TNF blockers in axial SpA – collaboration with Drs Raj Sengupta and Hannah Family, Department of Pharmacy and Pharmacology, University of Bath, Bath – grant application in preparation
- Cimzia in TNF inadequate responders – a 1 year observational study – in collaboration with UCB Pharma – grant application in preparation
- Quantification of bone marrow oedema using diffusion-weighted MRI in axial SpA – project in development – collaboration with Dr Donnie Cameron, UEA
- Impact of diet on disease characteristics in axSpA – Prof. Aedin Cassidy, UEA

## Research training:

- Arthritis Research Campaign Clinical Research Fellow, The Royal London Hospital Medical School (August 1993-December 1995).
- GCP Training – 28th July 2017

## Teaching/Training/Leadership Roles – Current

### NUUH/UEA

- Norwich Medical School - lecturer & personal tutor
- Host - Sixth form, student electives and physician assistants
- Organiser, NNUH Axial SpA Patient Information Day (2011-).
- Convenor, NNUH MSK update (2005-);
- Lecturer, MSc in Advanced MSK Research & Practice (UEA 2007-).
- Organiser, Norwich Axial SpA Clinical Observation Programme (2008-).
- Invited Member, Science and Strategy Steering Group, Quadram Institute, UEA (2016-)
- Invited Member CTU Executive Committee, UEA (2016-)
- Member, Trial Steering Committee methylphenidate in sarcoidosis - FAST-MP (2016-)
- Established post-CCT rheumatology fellowship post in 2016
- Lead, Biologics Dose Tapering, NNUH, secured 71K CCG investment - September 2017 - projected savings of 1.375 million over 3 yrs

### National

- Medical Advisor & Trustee NASS, (2010-), Chief Medical Advisor (2016-)
- Nominated Clinical Expert, The National Institute for Health & Care Excellence - Biological therapies in axial spondyloarthritis and ankylosing spondylitis (2005-) TA 143 (2008), TA 233 (2011), TA 383 (2016), TA 350 (2016)
- Chair, British Society for Rheumatology (BSR), Axial Spondyloarthritis Biologics Guidelines Committee (2012-)
- Rheumatology External Advisor, London Deanery, 75 Trainees ARCP/PYAs (2011-)
- Consultant Mentor, BSR (2012-)
- Chair/course organizer/speaker, "Evolution in Rheumatology" - 226 delegates since 2015 - consistently related as excellent by >90% of delegates
- Co-developed "Back in Focus"- [www.axialSpAbackinfoocus.co.uk](http://www.axialSpAbackinfoocus.co.uk) - an educational programme for UK healthcare professionals who are involved in the diagnosis and treatment of patients with axial spondyloarthritis (SpA -11 meetings 2012-2017 (626 delegates - rated good/excellent by 100%) - awarded an international "Communique award for Excellence in Meetings"-2014 & 2015.
- Co-developed "Meeting in a Box" in conjunction with NASS - a Primary Care Back Pain Educational Resource, launched at BSR AGM 2013 - 8 national seminars 2012-15 - 770 delegates - 100% rated good/excellent-now available on DVD – distributed to 36 countries
- Developed "Solving Spondyloarthritis" Podcast (March 2016) – trending at no. 1 on *itunes* March 2016 (Science & Medicine category) - 19,738 listens of over 90%, 55% UK based
- Developed an RCGP elearning educational programme on axial SpA (in conjunction with NASS & BRITSpA) – launched July 2017 <http://elearning.rcgp.org.uk/backpain>
- Co-developed "Back Pain Plus" <https://nass.co.uk/back-pain-plus> – 2016 – an axial SpA awareness campaign for ophthalmology, gastroenterology and dermatology – secured 50K from AbbVie

- Founder Member & Treasurer, BRITSpA (2014 -) – the only UK-based charity committed to advancing knowledge and treatment of spondyloarthritis – 146 members –hosted inaugural national scientific meeting 2015, established UK training fellowships & convenor of collaborative research projects, personally secured funding for a BRITSpA Research Fellow, Research Administrator, Annual National Scientific Meeting, BRITSpA Preceptorship and Travelling Fellowship >£500,00 since 2014 - [www.britspa.co.uk](http://www.britspa.co.uk)
- Co-founder and Chair, East of England (EOE) SpA Academy 2017 – developed to enhance SpA care - inaugural meeting September 2017 – 57 delegates representing 17 EOE NHS Trusts , 2<sup>nd</sup> event December 2017, further events planned for March and June 2018
- Lead, CAMSpA - NASS Complementary and Alternative Medicine Disease Awareness Project – 40K grant from UCB Pharma 2017

My medical leadership and charities work was acknowledged as an “Undercover Hero” in the Patient Choice Awards – House of Commons, November 2016

### International

- Invited Member, The Assessment of Spondyloarthritis International Society (ASAS) 2012-

### Publications

#### Original Articles

Influence of co-morbid fibromyalgia on disease activity measures and response to TNF inhibitors in axial spondyloarthritis: results from a UK national register. Macfarlane GJ, MacDonald R, Pathan E, Siebert S, **Gaffney K**, Choy E, Martin KR, Haywood K, Sengupta R, Atzenil F, Jones GT. *Rheumatology* 2018; Submitted

Definition and predictors of sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis. Yaha F, **Gaffney K**, Sengupta. *ARD* 2018; Submitted

The prevalence of axial spondyloarthritis in patients with acute anterior uveitis – a cross-sectional cohort study with MRI verification. Sykes M, Hamilton L, Jones C, **Gaffney K**. *RMD Open* 2018;4:e000553. doi:10.1136/rmdopen-2017-000553

Services for axial spondyloarthritis: A survey of patients and rheumatologists. Derakhshan M, Pathak H, Cook D, Dickinson S, Siebert S, **Gaffney K**. *Rheumatology* 2018; doi: 10.1093/rheumatology/kex518 [Epub ahead of print]

Tumour Necrosis Factor inhibitor survival and predictors of response in axial spondyloarthritis: Findings from a United Kingdom cohort. Yaha F, **Gaffney K**, Hamilton L, Lonsdale E, Leeder J, Brooksby A, Cavill C, Berry-Jenkins J, Boyle C, Bond D, Sengupta R. *Rheumatology (Oxford)*. 2017 Dec 20. doi: 10.1093/rheumatology/kex457. [Epub ahead of print]

Maintenance of low disease activity following TNF inhibitor dose tapering in Ankylosing Spondylitis. Steel, **Gaffney K**. *J Rheumatol*. 2017 Aug;44(8):1292

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Hamilton L, Barkham N, Bhalla A, Brittain R, Jones G, Mackay K, Marshall D, Marzo-Ortega H, Murphy D, Riddell C, Sengupta R, Siebert S, Van Rossen L, **Gaffney K**. *Rheumatology* 2017; 56:313-6.

Comment on “Delay to Diagnosis in Axial SpA: Are We Improving in the UK?”

Sykes M, Doll H, Sengupta R, **Gaffney K**. *Rheumatology* (Oxford) 2016; 55: 1707-8

Poor awareness of inflammatory back pain and axial spondyloarthritis amongst secondary care specialists. Mathieson HR, Merashli M, **Gaffney K**, Marzo-Ortega H. *Clin Rheumatol*. 2016 Oct; 35(10):2627-8.

Does the co-existence of acute anterior uveitis and chronic back pain prompt primary care physicians to consider a diagnosis of axial spondyloarthritis? Maxwell A, Yates M, Everden P, **Gaffney K**. *Ann Rheum Dis* 2016 Apr;75(4):e18. doi: 10.1136/annrheumdis-2015-208983. Epub 2016 Jan 20

The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study. Hamilton L, Macgregor A, Toms A, Warmington V, Pinch E, **Gaffney K**. *BMC Musculoskeletal Disorders* (2015) 16:392-6.

Delay to Diagnosis in Axial SpA: Are We Improving in the UK?  
Sykes M, Doll H, Sengupta R, **Gaffney K**. *Rheumatology* (Oxford). 2015; 54(12):2283-4

Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, Ward M, Gensler LS, Zhou X, Garchon HJ, Chiochia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Haroon N, Mulero J, Blanco FJ, Gonzalez-Gay MA, Lopez-Larrea C, Bowness P, **Gaffney K**, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Crusius JB, van der Horst-Bruinsma IE, Valle-Oñate R, Romero-Sánchez C, Hansen IM, Pimentel-Santos FM, Inman RD, Martin J, Breban M, Wordsworth BP, Reveille JD, Evans DM, de Bakker PI, Brown MA. *Nat Commun* 2015 May 21;6:7146. DOI: 10.1038/ncomms8146

Correlation between clinical and MRI disease activity scores in axial spondyloarthritis. MacKay J, Aboelmagd S, **Gaffney K**. *Clin Rheumatol* 2015 Sep;34(9):1633-8

An open label, pilot, multi-centre, step-down, randomised controlled-trial to examine whether etanercept 25mg once weekly is effective in maintaining a clinical response in patients with ankylosing spondylitis who have responded to 50mg once weekly – The ANSWERS trial. Yates M, Elender F, Hamilton L, Dean L, Doll H, Thomas J, **Gaffney K**. *J Rheum* 2015 Jul;42(7):1177-85

Comment on: 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry' by Sorensen *et al*. Sykes M, Doll H, **Gaffney K**. *Ann Rheum Dis* 2014;1. doi:10.1136/annrheumdis-2014-205589

Prevalence of Inflammatory Back Pain in a UK Primary Care Population. Hamilton LE, MacGregor AJ, Warmington V, Pinch E, **Gaffney K**. *Rheumatology* 2014; 53: 161-164

Validation of a patient self-reported screening questionnaire for axial spondyloarthropathy in a UK population. Hamilton L, Newman D, Belkhir A, Toms A, MacGregor A, **Gaffney K**. *Spine* (Phila Pa 1976) 2013 ;38(6):502-6

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, Cremin K, Pryce K, Harris J, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiochia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Kenna TJ, Haroon N, Ferreira MA, Yang J, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Deloukas P, Donnelly P; Australo-Anglo-American Spondyloarthritis Consortium (TASC); Groupe Française d'Etude Génétique des Spondylarthrites (GFEGS);

Nord-Trøndelag Health Study (HUNT); Spondyloarthritis Research Consortium of Canada (SPARCC); Wellcome Trust Case Control Consortium 2 (WTCCC2), Bowness P, Gaffney K, Gaston H, Gladman DD, Rahman P, Maksymowich WP, Xu H, Crusius JB, van der Horst-Bruinsma IE, Chou CT, Valle-Oñate R, Romero-Sánchez C, Hansen IM, Pimentel-Santos FM, Inman RD, Videm V, Martin J, Breban M, Reveille JD, Evans DM, Kim TH, Wordsworth BP, Brown MA. *Nat Genet.* 2013 Jul;45(7):730-8. doi: 10.1038/ng.2667. Epub 2013 Jun 9  
Influences of Inflammatory Polyarthritis on Quantitative Heel Ultrasound Measurements. SR Pye, T Marshall, **K Gaffney**, R Luben, KT Khaw, AJ Silman, DPM Symmons, TW O'Neill. *BMC Musculoskeletal Disorders* 2012; 13:133

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility Evans DM, Spencer CC, **Gaffney K** et al. Erratum in: *Nat Genet.* 2011 Sep; 43(9):919.

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowich W, Gladman D, Rahman P; Spondyloarthritis Research Consortium of Canada (SPARCC)., Morgan A, Marzo-Ortega H, Bowness P, **Gaffney K**, Gaston JS, Smith M, Bruges-Armas J, Couto AR, Sorrentino R, Paladini F, Ferreira MA, Xu H, Liu Y, Jiang L, Lopez-Larrea C, Díaz-Peña R, López-Vázquez A, Zayats T, Band G, Bellenguez C, Blackburn H, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Freeman C, Gillman M, Gray E, Gwilliam R, Hammond N, Hunt SE, Jankowski J, Jayakumar A, Langford C, Liddle J, Markus HS, Mathew CG, McCann OT, McCarthy MI, Palmer CN, Peltonen L, Plomin R, Potter SC, Rautanen A, Ravindrarajah R, Ricketts M, Samani N, Sawcer SJ, Strange A, Trembath RC, Viswanathan AC, Waller M, Weston P, Whittaker P, Widaa S, Wood NW, McVean G, Reveille JD, Wordsworth BP, Brown MA, Donnelly P. Australo-Anglo-American Spondyloarthritis Consortium (TASC).; Wellcome Trust Case Control Consortium 2 (WTCCC2). *Nat Genet.* 2011 Jul 10;43(8):761-7.

Services for people with ankylosing spondylitis in the UK. Hamilton L, Gilbert A, Skerrett J, Dickinson S, **Gaffney K**. *Rheumatology* 2011; 50: 1991-8.

Factors influencing recruitment to rheumatology. Watson P, **Gaffney K**. *Rheumatology* 2011; *Clinical Medicine* 2011; 11: 509-510.

Influence of arthritis and non-arthritis-related factors on areal bone mineral density (BMDa) in women with longstanding inflammatory polyarthritis: a primary care-based inception cohort. Pye SR, Marshall T, **Gaffney K**, Silman AJ, Symmons DP, O'Neill TW. *BMC Musculoskeletal Disord.* 2010 May 28; 11:106.

Comment on: Screening for MTB prior to anti-TNF therapy – an audit of impact of the BTS guidelines on rheumatology practice. JD Pradeep, GPR Clunie, **K Gaffney**, A Brooksby, NJ Innes, P Bradley, A Gulati. *Rheumatology* 2009; 48: 1332.

Screening for MTB prior to anti-TNF therapy – an audit of impact of the BTS guidelines on rheumatology practice. JD Pradeep, GPR Clunie, **K Gaffney**, A Brooksby, NJ Innes, P Bradley, A Gulati. *Rheumatology* 2009; 48: 195.

Switching anti-TNF therapy in ankylosing spondylitis. DJ Pradeep, AC Keat, **K Gaffney**, A Brooksby, J Leeder, C Harris. *Rheumatology* 2008; 47: 1726-7.

Recognition of Inflammatory Back Pain and Ankylosing Spondylitis in Primary Care. Jois RN, **Gaffney K**. *Rheumatology* 2008; 47; 1364-6.

The influence of biological therapy on return to work in people with work disability due to

ankylosing spondylitis. AC Keat, **K Gaffney**, AK Gilbert, C Harris, J Leeder. *Rheumatology* 2008; 47: 481-3.

Physical therapy in anti-TNF treated-patients with ankylosing spondylitis. SG Dubey, J Leeder, **K Gaffney**. *Rheumatology* 2008; 47: 1100-1.

Rituximab therapy in patients with resistant rheumatoid arthritis: real life experience. RN Jois, A Masding, M Somerville, **K Gaffney**, DGI Scott. *Rheumatology* 2007;46: 980-2

Demographic and Environmental Factors in a Wegener's Granulomatosis Cluster. J Lee, T Attygalle, **K Gaffney**, DGI Scott. *Ann Rheum Dis* 2007; 66: 278-9.

Patient Satisfaction With Rheumatology Practitioner Clinics: Can We Achieve Concordance by Meeting Patients' Information Needs and Encouraging Participatory Decision Making? AYN Lim, C Ellis, A Brooksby, **K Gaffney**. *Ann Acad Med (Singapore)* 2007; 36(2): 110-4.

Low dose infliximab treatment for ankylosing spondylitis: clinically and cost effective. RN Jois, J Leeder, A Gibb, **K Gaffney**, A MacGregor, M Somerville, DGI Scott. *Rheumatology* 2006;45: 1566-9.

Prevalence and associated factors for falls in women with established inflammatory polyarthritis. Anna E Oswald, Stephen R Pye, Terence W O'Neill, Diane Bunn, **Karl Gaffney**, Tarnya Marshall, Alan J Silman, Deborah PM Symmons. *J Rheumatol* 2006; 33(4): 690-4.

Comment on "Methotrexate-related pancytopenia.: serious and under-reported? Our experience of 25 cases in 5 years": reply. A. Lim, **K Gaffney**, DGI Scott. *Rheumatology* 2006; 45: 363-4

Methotrexate-related pancytopenia.: serious and under-reported? Our experience of 25 cases in 5 years. A. Lim, **K Gaffney**, DGI Scott. *Rheumatology* 2005; 44: 1051-55

BSR Guidelines for Prescribing TNF  $\square$ Blockers in Adults with Ankylosing Spondylitis. Report of a working party of the British Society for Rheumatology. A Keat, N Barkham, A Bhalla, **K Gaffney**, H Marzo-Ortega, S Paul, F Rogers, M Somerville, R Sturrock, P Wordsworth. *Rheumatology* 2005; 44: 939-47.

Benchmarking – the five-year outcome of rheumatoid arthritis assessed using a pain score, the health assessment questionnaire and the short form 36 (SF 36) in a community-based sample. N Wiles, DGI Scott, EM Barrett, P Merry, E Arie, **K Gaffney**, AJ Silman, DPM Symmons. *Ann Rheum Dis* 2001; 60: 956-61.

CD11b-positive blood lymphocytes correlate with disease activity in patients with rheumatoid arthritis. MG Macey, DA McCarthy, **K. Gaffney**, JD Perry, KA Brown, AC Newland. *Clin Exp Rheumatol* 1998; 16: 108-9.

Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA-enhanced magnetic resonance imaging. **K Gaffney**, J Cookson, S Blades, A Coumbe, DR Blake. *Ann Rheum Dis* 1998; 57: 152-7.

Intra-articular pressure profile of the knee joint in a spectrum of inflammatory arthropathies. S Jawed, **K Gaffney**, DR Blake. *Ann Rheum Dis* 1997; 56: 686-9.

Xanthine Oxidase: four roles for the enzyme in rheumatoid pathology. Blake DR, Stevens CR, Sahinoglu T, Ellis G, **Gaffney K**, Edmonds S, Benbouetra M, Harrison R, Jawed S, Kanczler, Millar TM, Winyard PG, Zhand Z. *Biochem Soc Trans* 1997; 25(3): 812-6.

A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid. L Dai, Z Zhang, PG Winyard, **K Gaffney**, H Jones, DR



Blake, CJ Morris. *Free Radic Biol Med* 1997; 22: 705-10.

Activation of the transcription factor NF- $\kappa$ B in human-inflamed synovial tissue. R Marok, PG Winyard, A Coumbe, ML Kus, **K Gaffney**, S Blades, PI Mapp, CJ Morris, DR Blake, C Kaltschmidt, PA Baeuerle. *Arthritis Rheum* 1996; 39: 583-91.

Quantification of rheumatoid synovitis by magnetic resonance imaging. **K Gaffney**, J Cookson, DR Blake, A Coumbe, S Blades. *Arthritis Rheum* 1995; 38: 1610-17

Intra-articular pressure changes in rheumatoid and normal peripheral joints. **K Gaffney**, RB Williams, V Jolliffe, DR Blake. *Ann Rheum Dis* 1995; 54: 670-673.

Intra-articular triamcinolone hexacetonide in knee osteoarthritis: Factors influencing the clinical response. **K Gaffney**, J Ledingham, JD Perry. *Ann Rheum Dis* 1995; 54: 379-381.

Detection and investigation of the molecular nature of low-molecular-mass copper ions in isolated rheumatoid knee-joint synovial fluid. D Naughton, J Knappitt, K Fairburn, **K Gaffney**, DR Blake, Grootveld M. *FEBS Letters* 1995; 361: 167-172.

Mucocutaneous criteria for the diagnosis of Behcet's disease: an analysis of clinicopathological data from multiple international centers. JL Jorizzo, JL Abernethy, WL White, HC Mangelsdorf, CC Zouboulis, R Sarica, **K Gaffney**, C Mat, H Yazici, et al. *J Am Acad Derm* 1995, 32: 968-976.

Elevated lipoprotein (A) in carotid-artery atherosclerosis is unrelated to restenosis after endarterectomy. J Stinson, G D'Arcy, T Cooke, MP Colgan, M Hall, J Tyrell, **K Gaffney**, M Grouden, DJ Moore, G Shanik, J Feely. *J Vasc Surg* 1995; 29: 23-27.

Neutrophil Collagenase in sputum from patients with cystic fibrosis. C Power, CM O'Connor, D McFarlane, S O'Mahony, **K Gaffney**, J Hayes, MX FitzGerald. *Am J Resp Crit Care Med* 1994; 150: 818-822.

$\alpha$ 1-Proteinase Inhibitor, Elastase activity and lung disease severity in cystic fibrosis. CM O'Connor, **K Gaffney**, J Keane, A Southey, N Byrne, S O'Mahony, MX Fitzgerald. *Am Rev Resp Dis* 1993; 148: 1665-70.

The Impact of HIV Disease on an Irish Prison Population. M Murphy, **K Gaffney**, O Carey, E Dooley, FM Mulcahy. *Int J of STD and AIDS* 1992; 3: 426-429.

Phlebotomy practice/needle stick injuries/hepatitis B status among interns in a Dublin hospital. **K Gaffney**, M Murphy, F Mulcahy. *Ir Med J* 1992; 85: 102-104.

## Editorials

The Clinical utility of HLA B27 in axial spondyloarthritis. Lim E, Sengupta R, **Gaffney K**. *Rheumatology (Oxford)*. 2017 Sep 25. doi: 10.1093/rheumatology/kex345. [Epub ahead of print]

Defining the target: clinical aims in ankylosing spondylitis. Marzo-Ortega H, Gaffney KM, **Gaffney K**. *Rheumatology* 2017; In press.

Should axial spondyloarthritis without radiographic change be treated with anti-TNF agents? Keat A, Bennett AN, **Gaffney K**, Marzo-Ortega H, Sengupta H, Siebert S, Everiss T. *Rheumatology Int* 2017; 37:327-36.

Do low-dose anti-TNF regimens have a role in patients with Ankylosing Spondylitis? Yates M, Keat A, **Gaffney K**. *Rheumatology* 2016; 55: 769-72.

Expanding the spectrum of inflammatory spinal disease. AS it was, as it is now. Isdale A, Keat A, Barkham N, Bennett A, **Gaffney K**, Marzo-Ortega H, Sengupta R. *Rheumatology* 2013;52:2103-5.

Improving the Treatment of Ankylosing Spondylitis in the UK. Keat A, **Gaffney K**, Cornell T, MacKay K, Marzo-Ortega H, Skerrett J, Van-Rossen L, Wordsworth P. *Rheumatology* 2011; 50: 1936-9.

Predicting Outcomes in Ankylosing Spondylitis. J. Pradeep, A. Keat, **K. Gaffney**. *Rheumatology* 2008; 47: 942-5.

Anti-tumour necrosis factor therapy for ankylosing spondylitis – unresolved issues. R Jois, **K Gaffney**, A. Keat. *Rheumatology* 2007; 46: 899-901.

Early Rheumatoid Arthritis – the changing scenario. RN Jois, **K Gaffney**. *J Rheumatology Occupational Therapy* 2007; 21: 6-8.

Early Rheumatoid Arthritis: approach to management. S Dubey, **K Gaffney**. *Clinical Medicine* 2005; 5: 211-3.

Azathioprine and Cyclophosphamide in the management of rheumatoid arthritis. **K Gaffney**, DGI Scott. *Br J Rheumatol* 1998; 37: 824-36.

The influence of intra-articular pressure changes on inflammatory arthritis. **K. Gaffney**, DR Blake. *Rheumatology in Europe* 1997; 26: 112-3.

Pressure and vascular changes in mobile joints: Implications for inflammatory joint disease. **K Gaffney**, SE Edmonds, CR Stevens, DR Blake. *Scand J Rheumatol* 1995; 23: 17-22.

Hypoxia and the rheumatoid joint: Immunological and therapeutic implications. SE Edmonds, G Ellis, **K Gaffney**, J Archer, DR Blake. *Scand J Rheumatol* 1995; 23: 151-156.

## **Case Reports**

Severe colitis complicating secukinumab therapy. Lee ASW, Levell NJ, Shah NS, **Gaffney K**, Tremelling MAW. *Clinical & Experimental Dermatology* 2018; Submitted

Scrotal calcinosis in an adult patient with amyotrophic dermatomyositis. Steel L, **Gaffney K**. *Rheumatology* 2018; Submitted

A lump in the wrist- proliferative tenosynovitis of fourth extensor compartment  
Achellios K, **Gaffney K**. *Rheumatology* 2018; Submitted

Sustained remission of type I diabetes following rituximab therapy. Robinson A, **Gaffney K**. *Rheumatology* 2017: Submitted

Large vessel vasculitis ; a rare but preventable cause of stroke. H Pathak, CY Yong, **K Gaffney**. *Indian J Rheumatol March 17, 2017, IP: 64.233.173.12*

Delayed presentation of Wegener's granulomatosis with pancreatic involvement. L. Hamilton, **K. Gaffney**, Andreou A, Saada J. *International Journal of Rheumatic Diseases* 2011; 14: 54-55.

An unusual case of chest pain. N Hassan, **K Gaffney**. *BMJ* 2008; 337: a898

Like father, like son. J Lee, P Merry, Ball R, **K. Gaffney**. *Ann Rheum Dis* 2007; 66: 1686-7

Spontaneous remission in Wegner's Granulomatosis. J Thomas, **K Gaffney**. *Scand J Rheumatol* 2007; 36: 324-6.

Methotrexate associated lymphoproliferative disorder masquerading as interstitial lung disease. R Jois, **K Gaffney**, P Cane, A Nicholson, A Wotherspoon. *Histopathology* 2007; 51:709-12

Juvenile onset spondylodiscitis - magnetic resonance imaging changes with Infliximab. A Lim, **K Gaffney**, T Marshall. *Rheumatology* 2004; 43:1456-8

Chronic Periaortitis, Idiopathic retroperitoneal fibrosis, Inflammatory aneurysm of abdominal aorta. RN Jois, **K Gaffney**, T Marshall, DGI Scott. *Rheumatology* 2004; 43:1441-6

A Pair of Buttocks. S Bawa, **K Gaffney**, TJ Marshall. *Rheumatology* 2004 ; 43:669-9

Intervertebral discitis presenting as oligoarthritis. T Marshall, **K Gaffney**. *Ann Rheum Dis* 2004; 63:634-5

Near fatal case of the dapsone hypersensitivity syndrome. KS Leslie, **K Gaffney**, CN Ross, S Ridley, TH Barker, J Garioch. *Clinical Dermatology* 2003; 28: 496-8

Rheumatoid Nodules. T Marshall, **K Gaffney**. *BMJ* 2002; 324: 858

A swollen leg unmasks longstanding SLE. SE Lane, **K Gaffney**, RY Ball, .M Marshall. *Lupus* 2001; 10: 4-8.

Ear, ear, what's going on in Norfolk. E Clarke, **K Gaffney**, P Merry, D. O'Gradaigh, D.Scott. *Ann Rheum Dis* 1999: 58; 660.

Unusual and memorable. Periostitis and bone proliferation. D O'Gradaigh, C Blundell, T Marshall, **K Gaffney**, P Chapman. *Ann Rheum Dis* 1999: 58; 263.

Interosseous nerve entrapment syndromes complicating inflammatory arthritis. **K Gaffney**, V Jolliffe, P Merry. *Clin Exp Rheumatol* 1997; 15: 339-40.

ANCA-positive polyarthritis associated with minocycline therapy. **K Gaffney**, P Merry. *Br J Rheumatol* 1996; 35: 1327.

Amyloidosis Complicating Cystic Fibrosis. **K Gaffney**, D Gibbons, B Keogh, MX FitzGerald. *Thorax* 1993; 48: 949-50.

Eosinophilic Fasciitis: A good response with conservative treatment. **K Gaffney**, G Kearns, D Moraes, JF O'Dowd, EB Casey. *Ir J Med Sci* 1993; 162: 256-7.

## Book Chapters

Spinal Pain. Hamilton L, **Gaffney K**. *Oxford Textbook of Rheumatology* 4<sup>th</sup> Edition; 87-91

**Signature:** KARL GAFFNEY

**Date:** 20/11/2017

--	--